KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) EBIT (2017 - 2025)

Guardant Health (GH) has disclosed EBIT for 9 consecutive years, with -$120.8 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 4.1% to -$120.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$437.2 million through Dec 2025, up 1.43% year-over-year, with the annual reading at -$437.2 million for FY2025, 1.43% up from the prior year.
  • EBIT hit -$120.8 million in Q4 2025 for Guardant Health, down from -$99.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$97.6 million in Q2 2021 to a low of -$197.5 million in Q4 2023.
  • Historically, EBIT has averaged -$120.0 million across 5 years, with a median of -$115.4 million in 2023.
  • Biggest five-year swings in EBIT: tumbled 208.96% in 2021 and later skyrocketed 36.22% in 2024.
  • Year by year, EBIT stood at -$98.2 million in 2021, then plummeted by 48.79% to -$146.1 million in 2022, then crashed by 35.17% to -$197.5 million in 2023, then surged by 36.22% to -$126.0 million in 2024, then increased by 4.1% to -$120.8 million in 2025.
  • Business Quant data shows EBIT for GH at -$120.8 million in Q4 2025, -$99.0 million in Q3 2025, and -$106.4 million in Q2 2025.